Hydrocortisone for COVID-19 and Severe Hypoxia (COVID STEROID)
Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial
Sponsor: Aarhus University Hospital
This PHASE3 trial investigates Covid-19 and Hypoxia and is currently completed. Aarhus University Hospital leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 4 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE3
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aarhus University Hospital
- Copenhagen Trial Unit, Center for Clinical Intervention Research
- Rigshospitalet, Denmark
- Scandinavian Critical Care Trials Group
- University of Copenhagen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus, Denmark , Copenhagen, Denmark , Herlev, Denmark , Hillerød, Denmark , Hvidovre, Denmark , Kolding, Denmark , Køge, Denmark , Odense, Denmark , Roskilde, Denmark , Slagelse, Denmark and 1 more location